Selected articles
Articles for label Rušarová Nikol are displayed.. Show all articles
Prostate cancer – sequencing of systemic treatment of systemic disease – case report
02/2021 MUDr. Nikol Rušarová; MUDr. Hana Študentová, Ph.D.
Prostate cancer is one of the most common cancers in men worldwide. Many patients have and advanced disease despite of early diagnosis. Finding the optimal treatment sequencing in advanced prostate cancer is currently one of the most common question.
ENTIRE ARTICLE
Prostate cancer is one of the most common cancers in men worldwide. Many patients have and advanced disease despite of early diagnosis. Finding the optimal treatment sequencing in advanced prostate cancer is currently one of the most common question.
Atezolizumab in breast cancer therapy
02/2020 MUDr. Nikol Rušarová; MUDr. Marie Bartoušková
Breast cancer is the most frequently diagnosed cancer of women (except of skin tumors). In addition, up to 30 percent of women with early-stage, non-metastatic breast cancer at diagnosis will develop distant metastatic disease. Currently due to preventive examinations and mammography examination the incidence of breast cancer is increasing, which was 146 women / 100 000 inhabitants in 2017. But mortality decreases due to new possibilities of treatment and enlargement of the treatment armamentarium. In 2017 the mortality rate was 34.7 women / 100 000 inhabitants.
ENTIRE ARTICLE
Breast cancer is the most frequently diagnosed cancer of women (except of skin tumors). In addition, up to 30 percent of women with early-stage, non-metastatic breast cancer at diagnosis will develop distant metastatic disease. Currently due to preventive examinations and mammography examination the incidence of breast cancer is increasing, which was 146 women / 100 000 inhabitants in 2017. But mortality decreases due to new possibilities of treatment and enlargement of the treatment armamentarium. In 2017 the mortality rate was 34.7 women / 100 000 inhabitants.
HITHOC – possibility of combined treatment of malignant pleural mesothelioma
05/2019 Doc. MUDr. David Vrána, Ph.D.; MUDr. Nikol Rušarová; MUDr. Marek Szkorupa, Ph.D.
Malignant pleural mesothelioma represents a disease with poor prognosis. There is currently no accepted general standard of care however as available published data indicate the multimodality approach combining chemotherapy (neoadjuvant or adjuvant, based on cisplatin/carboplatin and pemetrexed), surgery and eventually perioperative pleural chemotherapy lavage seem to bring the most benefit. This approach is suitable for only limited group of patients in a good performance status, without any distant metastatic disease and without clinically significant comorbidities. Further research is therefore needed to define the optimal treatment algorithm for malignant pleural mesothelioma.
ENTIRE ARTICLE
Malignant pleural mesothelioma represents a disease with poor prognosis. There is currently no accepted general standard of care however as available published data indicate the multimodality approach combining chemotherapy (neoadjuvant or adjuvant, based on cisplatin/carboplatin and pemetrexed), surgery and eventually perioperative pleural chemotherapy lavage seem to bring the most benefit. This approach is suitable for only limited group of patients in a good performance status, without any distant metastatic disease and without clinically significant comorbidities. Further research is therefore needed to define the optimal treatment algorithm for malignant pleural mesothelioma.
Current treatment management of metastatic HER-2+/HER-2- breast cancer
02/2019 MUDr. Nikol Rušarová, MUDr. Marie Bartoušková, doc. MUDr. David Vrána, Ph.D.
Breast cancer is the most frequently diagnosed cancer and despite the gains in early detection, up to 5 percent of women are diagnosed with metastatic disease at the time of first presentation. Due to development of new molecules breast cancer is now a chronic disease, while metastatic disease is still incurable. It is a heterogeneous diverse disease composed of several biologic subtypes that have distinct behaviors and responses to therapy.
ENTIRE ARTICLE
Breast cancer is the most frequently diagnosed cancer and despite the gains in early detection, up to 5 percent of women are diagnosed with metastatic disease at the time of first presentation. Due to development of new molecules breast cancer is now a chronic disease, while metastatic disease is still incurable. It is a heterogeneous diverse disease composed of several biologic subtypes that have distinct behaviors and responses to therapy.